Bone Quality and Fractures in Women With Osteoporosis Treated With Bisphosphonates for 1 to 14 Years
JBMR Plus, 2021 Oral bisphosphonates are the primary medication for osteoporosis, but concerns exist regarding potential bone‐quality changes or low‐energy fractures.
Hartmut H Malluche +5 more
doaj +1 more source
Incidence and Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients Having Undergone Autologous Stem Cell Transplantation [PDF]
, 2012 Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy. Due to their long survival and subsequently high cumulative doses of bisphosphonates, multiple myeloma patients have the highest risk ...
Baumann, Philipp +9 more
core +1 more source
The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention [PDF]
, 2018 Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it is a potentially painful and debilitating condition that can considerably affect the quality of life of patients ...
Bedogni, Alberto +7 more
core +2 more sources
Decreased risk of breast cancer associated with oral bisphosphonate therapy [PDF]
, 2012 Preclinical studies and adjuvant trials using bisphosphonates have found them to have an antitumor effect. Although major advances have been made in chemoprevention strategies with selective estrogen receptor modulators and aromatase inhibitors, their ...
Brufsky, A, Mathew, A
core +2 more sources
Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model
BMC Musculoskeletal Disorders, 2017 Background Initial micromotion of a total hip replacement is associated with aseptic loosening. The use of bisphosphonates could be one way to reduce peri-implant bone resorption induced by micromotion.
Thomas Jakobsen +5 more
doaj +1 more source
Drugs in Context, 2020 Background: On stopping bisphosphonate treatment, bone resorption may increase before evidence of a decrease in bone density. Offset of bisphosphonate effect may therefore be monitored by measuring C-terminal telopeptide (CTX) following long-term ...
Louise Statham +2 more
doaj +1 more source
mBio, 2022 Prenyldiphosphate synthases catalyze the reaction of allylic diphosphates with one or more isopentenyl diphosphate molecules to form compounds such as farnesyl diphosphate, used in, e.g., sterol biosynthesis and protein prenylation, as well as longer ...
Melissa A. Sleda +9 more
doaj +1 more source
Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients
Frontiers in Pharmacology, 2018 Objective: To examine the incidence rates and association between dose-intensity, stratified by exposure duration, of bisphosphonates and the risk of osteonecrosis of the jaw among Korean osteoporotic patients older than 50 years.
Sung-mok Jung +2 more
doaj +1 more source
Medication-related osteonecrosis of the jaw: clinical and practical guidelines [PDF]
, 2016 Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, consisting of progressive bone destruction in the maxillofacial region of patients.
Allen +42 more
core +2 more sources
Clinical Case Reports, 2023 Key Clinical Message Chronic use of bisphosphonates, in combination with immunosuppressive therapy, increases the risk of jaw osteonecrosis. When sepsis occurs in patients receiving bisphosphonate, osteonecrosis of the jaw should be considered a ...
Kazuhiko Iwasaki, Akihito Okazaki
doaj +1 more source